The changing treatment landscape in idiopathic pulmonary fibrosis.

Eur Respir Rev · 2015 · PMC9487773 · PMID 25726557

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significancep=0.14not close (p > 0.1)

While there were numerically fewer deaths in the nintedanib arm compared to placebo, this difference did not reach statistical significance (nintedanib group: HR 0.70 (95% CI 0.43–1.12), p=0.14) [ 18 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.